Overview

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

Status:
Terminated

Trial end date:
2010-11-01

Target enrollment:

Participant gender:

Summary

This was a four month dose ranging study followed by a 24 to 48 month extension at the selected dose to characterize the safety and efficacy of the injectable IL-1B (interleukin 1, beta) antagonist canakinumab in the treatment of patients with Type 2 diabetes mellitus (T2DM) already treated on maximum dose metformin.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Antibodies, Monoclonal
Insulin Glargine
Metformin